BioLineRx Ltd.
BLRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001498403
No open-market purchases or sales by BioLineRx Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $206.7K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in BioLineRx Ltd. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 26
- +6 vs. Q1 2023
- Shares held
- 1.24M
- −2.05M (−62.3%) vs. Q1 2023
- Total value
- $1.97M
- −$939.9K (−32.3%) vs. Q1 2023
- New holders
- 9
- 2 more added
- Sold out
- 3
- 6 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BLRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $206.7K |
| Q1 2026 | 13 | $45.2K |
| Q4 2025 | 14 | $135.6K |
| Q3 2025 | 14 | $104.3K |
| Q2 2025 | 17 | $302.1K |
| Q1 2025 | 12 | $28.0K |
| Q4 2024 | 32 | $435.9K |
| Q3 2024 | 32 | $1.34M |
| Q2 2024 | 31 | $2.42M |
| Q1 2024 | 28 | $1.47M |
| Q4 2023 | 29 | $1.75M |
| Q3 2023 | 29 | $2.46M |
| Q2 2023 | 26 | $1.97M |
| Q1 2023 | 20 | $2.91M |
| Q4 2022 | 18 | $3.37M |
| Q3 2022 | 28 | $10.3M |
| Q2 2022 | 28 | $1.36M |
| Q1 2022 | 26 | $1.99M |
| Q4 2021 | 30 | $5.09M |
| Q3 2021 | 30 | $6.69M |
| Q2 2021 | 30 | $4.01M |
| Q1 2021 | 29 | $13.5M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding BioLineRx Ltd.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 260,976 | $416.3K | 0.00% | +4,064+1.6% | Added |
| Citadel Advisors LLC | 212,769 | $339.4K | 0.00% | +212,769 | New |
| LPL Financial LLC | 125,210 | $199.7K | 0.00% | +7,500+6.4% | Added |
| Atria Wealth Solutions, Inc. | 110,366 | $176.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 98,710 | $157.0K | 0.00% | −7,379−7.0% | Reduced |
| Susquehanna International Group, LLP | 84,098 | $134.1K | 0.00% | +84,098 | New |
| Envestnet Asset Management Inc | 68,425 | $109.1K | 0.00% | −30,491−30.8% | Reduced |
| PVG Asset Management Corp | 61,840 | $98.6K | 0.43% | −66,885−52.0% | Reduced |
| Geode Capital Management, LLC | 32,026 | $51.1K | 0.00% | 00.0% | Unchanged |
| Geneos Wealth Management Inc. | 23,500 | $37.6K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 19,901 | $31.7K | 0.00% | −11,052−35.7% | Reduced |
| Cutter & CO Brokerage, Inc. | 16,667 | $26.7K | 0.01% | 00.0% | Unchanged |
| Creative Planning | 14,582 | $23.3K | 0.00% | 00.0% | Unchanged |
| Cetera Investment Advisers | 14,265 | $22.8K | 0.00% | −5,738−28.7% | Reduced |
| Rhumbline Advisers | 13,585 | $21.7K | 0.00% | +13,585 | New |
| HRT Financial LP | 13,422 | $21.0K | 0.00% | +13,422 | New |
| Great Valley Advisor Group, Inc. | 12,300 | $20.0K | 0.00% | +12,300 | New |
| Nemes Rush Group LLC | 12,000 | $19.1K | 0.00% | +12,000 | New |
| National Asset Management, Inc. | 11,300 | $18.0K | 0.00% | +11,300 | New |
| Virtu Financial LLC | 11,545 | $18.0K | 0.00% | +11,545 | New |
| UBS Group AG | 10,537 | $16.8K | 0.00% | +10,537 | New |
| GWM Advisors LLC | 4,300 | $6.86K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 3,088 | $4.92K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 2,053 | $3.00K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 35 | $56 | 0.00% | 00.0% | Unchanged |
| Ronald Blue Trust, Inc. | 102 | $0 | 0.00% | −37−26.6% | Reduced |
| Altium Capital Management LP | 0 | $0 | 0.00% | −2,279,657−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −24,154−100.0% | Sold out |
| Belpointe Asset Management LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |